# 1. Financial Performance ## A. Key Figures * **PAT (9M):** **₹208 Cr** (+74% YoY) from ₹120 Cr * **Q3 PAT:** **₹77 Cr** (+28.3% YoY) despite ₹20 Cr one-off expense * GWP Growth: 26% for 9 months vs. 13% expense growth (strong operating leverage) * EOM Ratio: 35% (w/o 1/N, from 39% prior year); 36.3% (with 1/N) * **Balance Sheet:** **₹9,000 Cr AUM**, **3% investment yield**, **solvency ratio of 249** ## B. Revenue Growth * **Accelerating Momentum:** Volume and ticket size both showed marked improvement in Q3 versus H1, signaling stronger customer engagement and pricing power. * **Resilience Amid Headwinds:** Growth sustained despite GST-related drag on non-commissioned services and one-off labor code costs. ## C. Profitability Trends * **Robust Bottom-Line Expansion:** 9M PAT surged on strong GWP growth and disciplined cost control, with operating leverage clearly evident. * **IFRS Loss Ratio at Record Low:** Q3 loss ratio of **4%** underscores underwriting discipline, though full results await auditor review. * **Regulatory Compliance & Accounting Clarity:** Company remains compliant on EOM both with and without 1/N; latter is **40 bps higher**, indicating minimal impact. ## D. Expense Ratio * **Structural EOM Improvement:** Significant reduction in management expense ratio driven by lower gross commission as % of GWP, now at **21%** in Q3 from ~23% in H1. * **GST and Mix Dynamics:** Commission ratio compression reflects GST pass-through and shift toward higher new business, partially offsetting retail book adjustments. ## E. Balance Sheet Health * **Strong Capital Position:** High solvency ratio and solid investment yield reflect prudent capital management despite decline from prior highs. * **Growth-Focused Capital Allocation:** Initiatives prioritized to sustain growth, enhance returns, and navigate claims volatility and regulation. --- # 2. Product & Segment Performance ## A. Key Figures * **Growth Rate:** **26%** overall 9-month (+31% in Q3) · **33%** retail 9-month * **New Business Growth:** **46%** in Q3 · **30%** YTD * **PAT:** **₹208 Cr** (9-month) * **Market Share:** Rose to **10%** (9-month) from 6% in H1 * **Channel Growth:** **43%** Q3 in agency (+32% YTD) · **27.5%** Q3 in banca/NBFC (+19% YTD) ## B. Retail vs Group * **Retail Outperformance:** Retail segment significantly outpaced corporate business, which grew at just **12%**, reflecting selective underwriting and pricing discipline over volume-driven EoM compliance. * **Pricing & Portfolio Quality:** Annual high single-digit price increases tied to medical inflation ensure sustainability, avoiding **sticker shock** and **selective lapses**; renewal up-sell achieved with **nearly one in five eligible customers**. * **Stable Policy Mix:** Multi-year policies consistently represent **20%-21% of total premium**, with no material shifts in new business composition. ## C. New Product Launches * **Reassure 0 Gains Traction:** New flagship product emerged as the **fastest-growing** post-launch, targeting medical inflation with **lifetime coverage**, **unlimited sum insured**, and **comprehensive OPD/wellness benefits**. * **Enhanced Customer Experience:** **Niva Bupa One** membership delivers premium services including **top-tier health checkups** and **end-to-end claims support**, differentiating the offering. * **High Customization:** Product allows tailored coverage via **global benefits**, **flexible waiting periods**, and **adjustable co-pays/deductibles**. ## D. Channel Mix * **Agency Channel Strength:** Agency drove strong momentum with **robust double-digit growth**, outpacing other channels and signaling effective field force execution. * **Banca/NBFC Resilience:** Despite slower B2B growth overall, banca and NBFC partnerships delivered **solid year-to-date expansion**, with near-**20% YTD growth** and stable Q3 performance. --- # 3. Claims & Underwriting Discipline ## A. Key Figures * Combined Ratio (COR): 102.9% IFRS (9M, -50 bps) · 102.6% excluding one-off * **Claim Settlement Ratio:** ~95% (best-in-class) * Retail Loss Ratio (IFRS): 66.9% (9M) vs. 67% prior year * **Retail Claim Loss Ratio:** ~67% (stable despite growth) * **Group Loss Ratio:** 62% (9M) vs. 57% prior year * **NPS:** 58 blended (+5 pts) · 67 cashless ## B. Loss Ratio Trends * **COR Improvement Driven by Expense Discipline:** Strong reduction in expense ratio more than offset a slight uptick in loss ratio, with mix change being the primary driver of loss ratio movement. * **Retail Stability Amid Growth:** Retail claim loss ratio held steady at ~67% even with significant new business inflow—suggesting offsetting pressures in claims experience. * **Group Mix Shifts Weigh on Loss Ratio:** Increase in group loss ratio attributed to business mix; outlook improves as shift toward benefit-based products accelerates. * **Claims Performance Resilient:** Despite aging policyholder base and medical inflation, claims ratio remained flat YoY—indicating effective underwriting and industry-wide stabilization. * **Transitory Q3 Impacts:** Net neutral effect on COR from offsetting GST-related expense headwinds and lower medicine costs, both impacting Q3 by ~50 bps. ## C. Medical Cost Control * **Cost Inflation Benign So Far:** First 9 months of FY26 saw manageable medical cost trends, validating current pricing adequacy. * **Active Claims Cost Management:** Focus on preferred provider networks and medical protocols to control costs while enhancing customer experience. ## D. Admission Protocols * **Protocols Reduce Unwarranted Admissions:** Standardized, clinically driven admission rules prevent unnecessary hospitalizations, lowering claims and improving customer outcomes. * **Industry-Aligned Design:** Protocols developed with hospital input ensure clarity, reduce disputes, and prevent consumer inconvenience during claims. --- # 4. Technology & Innovation ## A. Key Figures * **Digital Channel Growth:** **70%** QoQ growth in Q3 · **49%** overall growth rate ## B. AI Integration * **AI Lab Operational:** Company has established a functioning AI Lab driving value chain transformation using both traditional AI and generative AI (Gen AI). * **Sprinkler Live:** Key AI-driven initiative "Sprinkler" is now live, with AI capabilities being progressively embedded into core products. ## C. Lifetime Value Model * **Predictive Underwriting Core:** Underwriting framework built on a proprietary lifetime value algorithm developed over nearly 6 years enables cohort behavior prediction and long-term claim discipline. * **Sustainable Growth Enabler:** Model supports disciplined portfolio expansion by evaluating risk sustainability across product, geography, channel, and customer demographics. ## D. Digital Channel Growth * **Robust Digital Traction:** Digital direct channel delivered strong momentum with near-half growth overall and **70% surge in Q3**, boosted by GST tailwinds and positive market adoption. --- # 5. Industry & Regulatory Initiatives ## A. Key Figures * **Insurance Awareness Spend:** **₹120–140 Cr** annually (industry-wide) * **Hospital Empanelment:** **1,000 hospitals** currently · expansion to **5,000 hospitals** in 6–9 months * **Healthcare Providers Consulted:** **10,000–15,000** in protocol development * **Commission Impact:** Gross commission ratio down **200 bps** (H1 to Q3) · **15–20%** of book impacted by senior trail reduction * **ICMR Protocols Adopted:** **100+** conditions, diagnoses, and procedures ## B. Common Empanelment * **Industry-Led Cost Control:** Collective bargaining has enabled common hospital empanelment with standardized tariffs, enhancing cost predictability and network scalability. * **Strategic Leadership:** Appointment of **Dr. Prakash** as CEO for Health at the General Insurance Council strengthens execution on common empanelment and clinical standardization. * **Scaled Network Expansion:** Live phase of empanelment underway, with significant near-term growth expected as network scales to **5,000 hospitals**. ## C. Standard Treatment Protocols * **Clinical Standardization Drive:** Industry has adopted **ICMR-backed treatment protocols** for over 100 conditions, reducing ambiguity in care and curbing over-treatment. * **Evidence-Based Guidelines Finalized:** Protocols for **seven diseases and seven surgeries** are published and publicly accessible, promoting transparency and medical necessity validation. * **Long-Term Claims Discipline:** Combined use of standardized care pathways and common empanelment supports appropriate care delivery at controlled costs, though financial impact remains unquantified. ## D. GST Impact * **Sustained GST Tailwinds:** Positive trends in volume and value persist into January, with December showing accelerated growth, indicating durable demand improvement. * **Commission Rationalization Complete:** Industry-wide pass-through of GST has reduced gross commission ratio and reset senior trail rates, with **no distributor pushback** due to offsetting volume gains. * **Regulatory Clarity Ahead:** Transition to **IFRS from April 2027** will harmonize reporting standards and eliminate current discrepancies. --- # 6. Risks & Regulatory Clarity ## A. Regulatory & Compliance Outlook * **Regulatory Clarity Achieved on Key Issues:** Exclusion of composite licensing, fee income from value-added services, and open architecture from the final Insurance Amendment Act removes uncertainty and affirms stable operating framework for Q. * **EoM Uncertainty Persists:** Despite IRDAI’s revised EoM calculation methodology sparking industry speculation, **no formal regulatory changes** have been confirmed; Niva Bupa remains focused on internal compliance and glide path adherence. ## B. Accounting & Reporting Framework * **IFRS Preferred Amid IGAAP Noise:** Management emphasizes **IFRS as the primary reporting standard** due to distortions in IGAAP, including lack of deferred acquisition costs (DAC) and recent methodological shifts. * **IGAAP Claims Ratio Distortions:** A **~8% gap** between IGAAP and IFRS claims ratios stems from structural factors: **50% earning basis with UPR offset**, **seasonality from large January group renewals**, and the new **1/N deferral method** for multi-year policies. --- # 7. Guidance & Outlook ## A. ROE Target * **Headline:** On track to achieve **high teens ROE** within two financial years under IFRS, driven by underwriting discipline, claims management, and operating leverage. * **Headline:** Sustained business growth and controlled loss ratios contributing to return on equity trajectory. ## B. Growth Trajectory * **Headline:** Brand-building initiatives supporting growth, with full impact expected over the long term in line with marketing cycle dynamics. * **Headline:** Solvency expected to remain above **200**, with no near-term plans for sub-debt issuance amid stable capital outlook.